-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Q/2SngyNfVmqjvc/7z5Li1qrsfdNAW0JQ3hAS+DsgGtOSRKQckcoqAGIR0AIrrla JKy4/jH/Ia280VDBthlvcQ== 0000950133-99-000541.txt : 19990222 0000950133-99-000541.hdr.sgml : 19990222 ACCESSION NUMBER: 0000950133-99-000541 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19990219 GROUP MEMBERS: BB BIOTECH AG GROUP MEMBERS: BIOTECH FOCUS S.A. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CLINICHEM DEVELOPMENT INC CENTRAL INDEX KEY: 0001054396 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-54385 FILM NUMBER: 99545508 BUSINESS ADDRESS: STREET 1: 275 ARMAND FRAPPIER BOULEVARD CITY: LAVAL PROVICE QUEBEC STATE: A8 ZIP: 00000 BUSINESS PHONE: 5146811744 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: DC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 2028351882 MAIL ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 SC 13G 1 SCHEDULE 13G RE: CLINICHEM DEVELOPMENT, INC. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ___________)* CLINICHEM DEVELOPMENT, INC. - -------------------------------------------------------------------------------- (Name of Issuer) CLASS A CALLABLE COMMON STOCK, NO PAR VALUE PER SHARE - -------------------------------------------------------------------------------- (Title of Class of Securities) 18690610 -------------------------- (CUSIP Number) JUNE 29, 1998 - -------------------------------------------------------------------------------- (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [ ] Rule 13d-1(c) [X] Rule 13d-1(d) 2 CUSIP No. 18690610 - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). BB BIOTECH AG - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Switzerland - -------------------------------------------------------------------------------- Number of 5. Sole Voting Power Shares Bene- ficially -0- Owned by Each Reporting --------------------------------------------------------------- Person With: 6. Shared Voting Power 172,187 --------------------------------------------------------------- 7. Sole Dispositive Power -0- --------------------------------------------------------------- 8. Shared Dispositive Power 172,187 - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 172,187 10. Check if the Aggregate Amount in Row (11) Excludes Certain shares 11. Percent of Class Represented by amount in Row (11) 6.3% - -------------------------------------------------------------------------------- 12. Type of Reporting Person (See Instructions) HC, CO - -------------------------------------------------------------------------------- Page 2 of 9 Pages 3 CUSIP No. 18690610 - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). BIOTECH FOCUS S.A. - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (a) (b) - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization PANAMA - -------------------------------------------------------------------------------- Number of 5. Sole Voting Power Shares Bene- ficially -0- Owned by Each Reporting --------------------------------------------------------------- Person With: 6. Shared Voting Power 172,187 --------------------------------------------------------------- 7. Sole Dispositive Power -0- --------------------------------------------------------------- 8. Shared Dispositive Power 172,187 - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 172,187 10. Check if the Aggregate Amount in Row (11) Excludes Certain shares 11. Percent of Class Represented by amount in Row (11) 6.3 % - -------------------------------------------------------------------------------- 12. Type of Reporting Person CO - -------------------------------------------------------------------------------- Page 3 of 9 Pages 4 ITEM 1. (a) Name of Issuer Clinichem Development, Inc. (b) Address of Issuer's Principal Executive Offices 275 Armand-Frappier Boulevard Laval, Quebec Canada H7V 4A7 ITEM 2. (a) Name of Person Filing BB Biotech AG ("BB Biotech") Biotech Focus S.A. ("Biotech Focus") (b) Address of Principal Business Office or, if none, Residence BB Biotech Biotech Focus Vordergasse 3 Swiss Bank Tower 8200 Schaffhausen Panama 1 CH/Switzerland Republic of Panama (c) Citizenship See Item No. 4 of cover pages. (d) Title of Class of Securities Class A Callable Common Stock, No Par Value Per Share (e) CUSIP Number 18690610 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO Sections 240.13D-1(b) OR 240.13D-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78c). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). Page 4 of 9 pages 5 (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [ ] An investment adviser in accordance with Section 240.13d-1(b)(1) (ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(J). ITEM 4. OWNERSHIP Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 172,187 (b) Percent of class: 6.3% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote -0- (ii) Shared power to vote or to direct the vote 172,187 (iii) Sole power to dispose or to direct the disposition of -0- (iv) Shared power to dispose or to direct the disposition of 172,187 Page 5 of 9 pages 6 ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]. ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. Not applicable. ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY This statement is filed jointly by BB Biotech and Biotech Focus. Biotech Focus is a wholly-owned subsidiary of BB Biotech. ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP Not applicable. ITEM 9. Not applicable. ITEM 10. CERTIFICATION By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Page 6 of 9 pages 7 SIGNATURES After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. BB BIOTECH AG Date: February 12, 1999 By: /s/ Hans-Joerg Graf ------------------------------ Name: Hans-Joerg Graf ---------------------------- Signatory Authority Date: February 12, 1999 By: /s/ Dr. Victor Bischoff ------------------------------ Name: Dr. Victor Bischoff ---------------------------- Vice Chairman and Director BIOTECH FOCUS, S.A. Date: February 12, 1999 By: /s/ Dr. Andreas Bremer ------------------------------ Name: Dr. Andreas Bremer ---------------------------- Signatory Authority Date: February 12, 1999 By: /s/ Dr. Daniel Bugmann ------------------------------ Name: Dr. Daniel Bugmann ---------------------------- Signatory Authority Page 7 of 9 pages 8 EXHIBIT INDEX Exhibit 1: Translation of minutes of the January 3, 1997 Board of Directors Meeting of Biotech Focus (evidencing a power of attorney in favor of Anders Hove, Hans Joerg Graf, Daniel Bugmann, Andreas Bremer and Nicolas Merian).* Exhibit 2: Translation of evidence of a power of attorney in favor of Victor Bischoff and Hans-Joerg Graf on behalf of BB Biotech.** Exhibit 3: Agreement by and between BB Biotech and Biotech Focus with respect to the filing of this disclosure statement.
- --------------------- * See Power of Attorney, previously filed as Exhibit 8 to the Schedule 13D relating to Biochem Pharma, Inc. filed with the Securities and Exchange Commission on July 23, 1998, which Exhibit is incorporated herein by reference. ** See Power of Attorney, previously filed as an Exhibit 99.E to the Schedule 13D relating to Biogen, Inc. filed with the Securities and Exchange Commission on June 2, 1994, which Exhibit is incorporated herein by reference. Page 8 of 9 pages 9 EXHIBIT 3 JOINT FILING AGREEMENT We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned. BB BIOTECH AG Date: February 12, 1999 By: /s/ Hans-Joerg Graf ----------------------------- Name: Hans-Joerg Graf --------------------------- Signatory Authority Date: February 12, 1999 By: /s/ Dr. Victor Bischoff ----------------------------- Name: Dr. Victor Bischoff --------------------------- Vice Chairman and Director BIOTECH FOCUS, S.A. Date: February 12, 1999 By: /s/ Dr. Andreas Bremer ----------------------------- Name: Dr. Andreas Bremer --------------------------- Signatory Authority Date: February 12, 1999 By: /s/ Dr. Daniel Bugmann ----------------------------- Name: Dr. Daniel Bugmann --------------------------- Signatory Authority Page 9 of 9 pages -----END PRIVACY-ENHANCED MESSAGE-----